Literature DB >> 25017675

Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.

Maria Jose Torres1, Esther Barrionuevo1, Marek Kowalski2, Miguel Blanca3.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the drugs most commonly involved in hypersensitivity drug reactions. Such reactions can be due to the release of inflammatory mediators in the absence of specific immunologic recognition, or immunoglobulin E (IgE)- or T-cell-selective responses. The former include upper and lower airway symptoms in patients with chronic underlying respiratory disease, the exacerbation of chronic spontaneous urticaria, and the induction of cutaneous symptoms. The latter include selective responses to a single NSAID with good tolerance to strong cyclooxygenase-1 inhibitors, with a putative IgE or T-cell mechanism proposed. These reactions can be acute or delayed.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergic; Clinical diagnosis; Hypersensitivity; Management; Nonallergic; Nonsteroidal anti-inflammatory drugs

Mesh:

Substances:

Year:  2014        PMID: 25017675     DOI: 10.1016/j.iac.2014.04.001

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  12 in total

Review 1.  Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice?

Authors:  Marek L Kowalski; Joanna S Makowska
Journal:  Allergy Asthma Immunol Res       Date:  2015-03-05       Impact factor: 5.764

2.  Asthma and Rhinitis Induced by Selective Immediate Reactions to Paracetamol and Non-steroidal Anti-inflammatory Drugs in Aspirin Tolerant Subjects.

Authors:  Diana Pérez-Alzate; Natalia Blanca-López; Inmaculada Doña; José A Agúndez; Elena García-Martín; José A Cornejo-García; James R Perkins; Miguel Blanca; Gabriela Canto
Journal:  Front Pharmacol       Date:  2016-07-20       Impact factor: 5.810

3.  Casticin inhibits interleukin-1β-induced ICAM-1 and MUC5AC expression by blocking NF-κB, PI3K-Akt, and MAPK signaling in human lung epithelial cells.

Authors:  Chian-Jiun Liou; Wen-Chung Huang
Journal:  Oncotarget       Date:  2017-09-15

4.  Mechanisms of hypersensitivity reactions induced by drugs.

Authors:  Fabrizio Franceschini; Paolo Bottau; Silvia Caimmi; Fabio Cardinale; Giuseppe Crisafulli; Lucia Liotti; Francesca Saretta; Roberto Bernardini; Francesca Mori; Carlo Caffarelli
Journal:  Acta Biomed       Date:  2019-01-28

5.  Direct in situ labeling of target drugs with a fluorophore probe to improve MALDI-MS detection sensitivity in micro-liter plasma.

Authors:  Yi-Shan Li; Chi-Yu Lu
Journal:  Sci Rep       Date:  2019-07-25       Impact factor: 4.379

6.  Clinical Manifestations and Causes of Anaphylaxis. Analysis of 382 Cases from the Anaphylaxis Registry in West Pomerania Province in Poland.

Authors:  Iwona Poziomkowska-Gęsicka; Michał Kurek
Journal:  Int J Environ Res Public Health       Date:  2020-04-17       Impact factor: 3.390

Review 7.  Safety issues of current analgesics: an update.

Authors:  Irina Cazacu; Cristina Mogosan; Felicia Loghin
Journal:  Clujul Med       Date:  2015-04-15

8.  A Randomized Clinical Trial of Nefopam versus Ketorolac Combined With Oxycodone in Patient-Controlled Analgesia after Gynecologic Surgery.

Authors:  Boo-Young Hwang; Jae-Young Kwon; Do-Won Lee; Eunsoo Kim; Tae-Kyun Kim; Hae-Kyu Kim
Journal:  Int J Med Sci       Date:  2015-07-30       Impact factor: 3.738

Review 9.  NSAID-induced reactions: classification, prevalence, impact, and management strategies.

Authors:  Natalia Blanca-Lopez; Victor Soriano; Elena Garcia-Martin; Gabriela Canto; Miguel Blanca
Journal:  J Asthma Allergy       Date:  2019-08-08

Review 10.  Safety of Non-Steroidal Anti-Inflammatory Drugs in the Elderly: An Analysis of Published Literature and Reports Sent to the Portuguese Pharmacovigilance System.

Authors:  Cristina Monteiro; Samuel Silvestre; Ana Paula Duarte; Gilberto Alves
Journal:  Int J Environ Res Public Health       Date:  2022-03-16       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.